Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is a feasibility study of the addition of domatinostat to pre-operative immune
checkpoint inhibitors in patients with muscle invasive urothelial cancer. This study can be
adapted or expanded to a phase 2 study based on results obtained.